Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication
December 08 2021 - 8:03AM
Stereotaxis (NYSE: STXS), the global leader in innovative
robotic technologies for the treatment of cardiac arrhythmias,
today announced a publication in Frontiers in Cardiovascular
Medicine titled “Atrial Fibrillation Ablation Using Robotic
Magnetic Navigation Reduces the Incidence of Silent Cerebral
Embolism.”
This multi-center, prospective study evaluated
166 patients with paroxysmal or persistent Atrial Fibrillation (AF)
who underwent pulmonary vein isolation using either Stereotaxis’
Robotic Magnetic Navigation (RMN) technology or manual contact
force ablation catheters. All patients received cerebral magnetic
resonance imaging within 48 hours before and after the ablation
procedure to assess cerebral embolism. Patients treated using RMN
had greater than 82% reduced incidence of silent cerebral embolism
(SCE) at 5.77% compared to 32.26% in patients treated with manual
catheter ablation (p<0.001). The study concluded, “ablation
technology is the only independent risk factor of SCEs, and RMN can
significantly reduce the incidence of SCEs resulting from AF
ablation.” This is the first study comparing incidence of SCEs
following cardiac ablation with RMN compared to manual catheters
and was performed independent of Stereotaxis in China by Wuxi
People’s Hospital, Fuwai Hospital, Xuzhou Central Hospital, and the
First Hospital Affiliated to Soochow University.
“The results of this study further strengthen
the significant safety and efficacy benefits we have experienced
using robotic technology to treat over 600 arrhythmia patients,”
said Dr. Ru-Xing Wang, Director of Cardiology at Wuxi People’s
Hospital. “We are grateful to offer our patients the best possible
care and look forward to advance clinical research and robotic
technology development.”
“This pioneering research on an often overlooked
aspect of cardiac ablation demonstrates that technology innovation
can meaningfully improve patient safety,” said Dr. Yan Yao,
Director of the Arrhythmia Center at Fuwai Hospital. “This strong
data supports our decision to build a world-class robotic cardiac
center of excellence in Beijing.”
Stereotaxis’ Robotic Magnetic Navigation
technology introduces the benefits of robotic precision and safety
to cardiac ablation, a common, minimally invasive procedure to
treat arrhythmias. Multiple studies have demonstrated reduced
incidences of heart perforation and other major adverse events from
the use of robotics for cardiac ablation when compared to manual
hand-held catheters. This is the first study assessing the impact
of robotics on silent cerebral emboli. Studies have demonstrated
that incurring acute cerebral lesions during cardiac ablation
procedures may be associated with longer-term adverse
neuropsychological outcomes such as an increased risk of stroke and
cognitive impairment.
The full publication can be found at
https://www.frontiersin.org/articles/10.3389/fcvm.2021.777355/full.
To access a complete database of more than 400 scientific
publications referencing Stereotaxis technology, visit
www.RoboticEP.com/clinical-data/publications-database/.
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024